LIVIVO - Search results -

Search results

Result 1 - 10 of total 12

Search options

Article: Identification of a Quinone Derivative as a YAP/TEAD Activity Modulator from a Repurposing Library.

Lauriola, Angela / Uliassi, Elisa / Santucci, Matteo / Bolognesi, Maria Laura / Mor, Marco / Scalvini, Laura / Elisi, Gian Marco / Gozzi, Gaia / Tagliazucchi, Lorenzo / Marverti, Gaetano / Ferrari, Stefania / Losi, Lorena / D'Arca, Domenico / Costi, Maria Paola

Pharmaceutics

2022 Volume 14, Issue 2

Abstract: The transcriptional regulators YAP (Yes-associated protein) and TAZ (transcriptional co-activator with PDZ-binding motif) are the major downstream effectors in the Hippo pathway and are involved in cancer progression through modulation of the activity of ...

Abstract	The transcriptional regulators YAP (Yes-associated protein) and TAZ (transcriptional co-activator with PDZ-binding motif) are the major downstream effectors in the Hippo pathway and are involved in cancer progression through modulation of the activity of TEAD (transcriptional enhanced associate domain) transcription factors. To exploit the advantages of drug repurposing in the search of new drugs, we developed a similar approach for the identification of new hits interfering with TEAD target gene expression. In our study, a 27-member in-house library was assembled, characterized, and screened for its cancer cell growth inhibition effect. In a secondary luciferase-based assay, only seven compounds confirmed their specific involvement in TEAD activity.
Language	English
Publishing date	2022-02-10
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	2527217-2
ISSN	1999-4923
ISSN	1999-4923
DOI	10.3390/pharmaceutics14020391
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Article: Structural Bases for the Synergistic Inhibition of Human Thymidylate Synthase and Ovarian Cancer Cell Growth by Drug Combinations.

Pozzi, Cecilia / Santucci, Matteo / Marverti, Gaetano / D'Arca, Domenico / Tagliazucchi, Lorenzo / Ferrari, Stefania / Gozzi, Gaia / Losi, Lorena / Tassone, Giusy / Mangani, Stefano / Ponterini, Glauco / Costi, Maria Paola

Cancers

2021 Volume 13, Issue 9

Abstract: Combining drugs represent an approach to efficiently prevent and overcome drug resistance and to reduce toxicity; yet it is a highly challenging task, particularly if combinations of inhibitors of the same enzyme target are considered. To show that ... ...

Abstract	Combining drugs represent an approach to efficiently prevent and overcome drug resistance and to reduce toxicity; yet it is a highly challenging task, particularly if combinations of inhibitors of the same enzyme target are considered. To show that crystallographic and inhibition kinetic information can provide indicators of cancer cell growth inhibition by combinations of two anti-human thymidylate synthase (hTS) drugs, we obtained the X-ray crystal structure of the hTS:raltitrexed:5-fluorodeoxyuridine monophosphate (FdUMP) complex. Its analysis showed a ternary complex with both molecules strongly bound inside the enzyme catalytic cavity. The synergistic inhibition of hTS and its mechanistic rationale were consistent with the structural analysis. When administered in combination to A2780 and A2780/CP ovarian cancer cells, the two drugs inhibited ovarian cancer cell growth additively/synergistically. Together, these results support the idea that X-ray crystallography can provide structural indicators for designing combinations of hTS (or any other target)-directed drugs to accelerate preclinical research for therapeutic application.
Language	English
Publishing date	2021-04-24
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	2527080-1
ISSN	2072-6694
ISSN	2072-6694
DOI	10.3390/cancers13092061
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Involvement of epigenetic modification of TERT promoter in response to all-trans retinoic acid in ovarian cancer cell lines.

Losi, Lorena / Lauriola, Angela / Tazzioli, Erica / Gozzi, Gaia / Scurani, Letizia / D'Arca, Domenico / Benhattar, Jean

Journal of ovarian research

2019 Volume 12, Issue 1, Page(s) 62

Abstract: Background: All-trans retinoic acid (ATRA) is currently being used to treat hematological malignancies, given the ability to inhibit cell proliferation. This effect seems to be related to epigenetic changes of the TERT (Telomerase Reverse Transcriptase) ...

Abstract	Background: All-trans retinoic acid (ATRA) is currently being used to treat hematological malignancies, given the ability to inhibit cell proliferation. This effect seems to be related to epigenetic changes of the TERT (Telomerase Reverse Transcriptase) promoter. When hypomethylated, ATRA-inducible TERT repressors can bind the promoter, repressing transcription of TERT, the rate-limiting component of telomerase. Ovarian carcinomas are heterogeneous tumors characterized by several aberrantly methylated genes among which is TERT. We recently found a hypomethylation of TERT promoter in about one third of serous carcinoma, the most lethal histotype. Our aim was to investigate the potential role of ATRA as an anticancer drug in a sub-group of ovarian carcinoma where the TERT promoter was hypomethylated. Methods: The potential antiproliferative and cytotoxic effect of ATRA was investigated in seven serous ovarian carcinoma and one teratocarcinoma cell lines and the results were compared to the methylation status of their TERT promoter. Results: The serous ovarian carcinoma cell line OVCAR3, harboring a hypomethylated TERT promoter, was the best and fastest responder. PA1 and SKOV3, two cell lines with an intermediate methylated promoter, revealed a weaker and delayed response. On the contrary, the other 5 cell lines with a highly methylated promoter did not respond to ATRA, indicative of ATRA-resistant cells. Conclusions: Our results demonstrate an inverse correlation between the methylation level of TERT promoter and ATRA efficacy in ovarian carcinoma cell lines. Although these results are preliminary, ATRA treatment could become a new powerful, personalized therapy in serous ovarian carcinoma patients, but only in those with tumors harboring a hypomethylated TERT promoter.
MeSH term(s)	Antineoplastic Agents/pharmacology ; Antineoplastic Agents/therapeutic use ; Cell Line, Tumor ; Cell Proliferation/drug effects ; Cell Survival/drug effects ; Cystadenocarcinoma, Serous/drug therapy ; Cystadenocarcinoma, Serous/genetics ; Cystadenocarcinoma, Serous/pathology ; DNA Methylation ; Drug Resistance, Neoplasm ; Epigenesis, Genetic ; Female ; Gene Expression/drug effects ; Humans ; Ovarian Neoplasms/drug therapy ; Ovarian Neoplasms/genetics ; Ovarian Neoplasms/pathology ; Promoter Regions, Genetic/genetics ; Telomerase/genetics ; Tretinoin/pharmacology ; Tretinoin/therapeutic use
Chemical Substances	Antineoplastic Agents ; Tretinoin (5688UTC01R) ; TERT protein, human (EC 2.7.7.49) ; Telomerase (EC 2.7.7.49)
Language	English
Publishing date	2019-07-10
Publishing country	England
Document type	Journal Article
ZDB-ID	2455679-8
ISSN	1757-2215 ; 1757-2215
ISSN (online)	1757-2215
ISSN	1757-2215
DOI	10.1186/s13048-019-0536-y
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: The 1,10-Phenanthroline Ligand Enhances the Antiproliferative Activity of DNA-Intercalating Thiourea-Pd(II) and -Pt(II) Complexes Against Cisplatin-Sensitive and -Resistant Human Ovarian Cancer Cell Lines.

Marverti, Gaetano / Gozzi, Gaia / Lauriola, Angela / Ponterini, Glauco / Belluti, Silvia / Imbriano, Carol / Costi, Maria Paola / D'Arca, Domenico

International journal of molecular sciences

2019 Volume 20, Issue 24

Abstract: Ovarian cancer is the most lethal gynecological malignancy, often because of the frequent insurgence of chemoresistance to the drugs currently used. Thus, new therapeutical agents are needed. We tested the toxicity of 16 new DNA-intercalating agents to ... ...

Abstract	Ovarian cancer is the most lethal gynecological malignancy, often because of the frequent insurgence of chemoresistance to the drugs currently used. Thus, new therapeutical agents are needed. We tested the toxicity of 16 new DNA-intercalating agents to cisplatin (cDDP)-sensitive human ovarian carcinoma cell lines and their resistant counterparts. The compounds were the complexes of Pt(II) or Pd(II) with bipyridyl (bipy) and phenanthrolyl (phen) and with four different thiourea ancillary ligands. Within each of the four series of complexes characterized by the same thiourea ligand, the Pd(phen) drugs invariably showed the highest anti-proliferative efficacy. This paralleled both a higher intracellular drug accumulation and a more efficient DNA intercalation than all the other metal-bidentate ligand combinations. The consequent inhibition of topoisomerase II activity led to the greatest inhibition of DNA metabolism, evidenced by the inhibition of the expression of the folate cycle enzymes and a marked perturbation of cell-cycle distribution in both cell lines. These findings indicate that the particular interaction of Pd(II) with phenanthroline confers the best pharmacokinetic and pharmacodynamic properties that make this class of DNA intercalators remarkable inhibitors, even of the resistant cell growth.
MeSH term(s)	Cell Cycle Checkpoints/drug effects ; Cell Line, Tumor ; Cell Proliferation/drug effects ; Cisplatin/pharmacology ; Coordination Complexes/chemistry ; Coordination Complexes/metabolism ; Coordination Complexes/pharmacology ; DNA/chemistry ; DNA/metabolism ; DNA Topoisomerases, Type II/chemistry ; DNA Topoisomerases, Type II/metabolism ; Drug Resistance, Neoplasm/drug effects ; Female ; Humans ; Intercalating Agents/chemistry ; Intercalating Agents/pharmacology ; Ligands ; Ovarian Neoplasms/metabolism ; Ovarian Neoplasms/pathology ; Palladium/chemistry ; Phenanthrolines/chemistry ; Platinum/chemistry ; Thiourea/chemistry
Chemical Substances	Coordination Complexes ; Intercalating Agents ; Ligands ; Phenanthrolines ; Platinum (49DFR088MY) ; Palladium (5TWQ1V240M) ; DNA (9007-49-2) ; DNA Topoisomerases, Type II (EC 5.99.1.3) ; Thiourea (GYV9AM2QAG) ; Cisplatin (Q20Q21Q62J) ; 1,10-phenanthroline (W4X6ZO7939)
Language	English
Publishing date	2019-12-04
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	2019364-6
ISSN	1422-0067 ; 1422-0067 ; 1661-6596
ISSN (online)	1422-0067
ISSN	1422-0067 ; 1661-6596
DOI	10.3390/ijms20246122
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: A Peptidic Thymidylate-Synthase Inhibitor Loaded on Pegylated Liposomes Enhances the Antitumour Effect of Chemotherapy Drugs in Human Ovarian Cancer Cells.

Marverti, Gaetano / Gozzi, Gaia / Maretti, Eleonora / Lauriola, Angela / Severi, Leda / Sacchetti, Francesca / Losi, Lorena / Pacifico, Salvatore / Ferrari, Stefania / Ponterini, Glauco / Leo, Eliana / Costi, Maria Paola / D'Arca, Domenico

International journal of molecular sciences

2020 Volume 21, Issue 12

Abstract: There is currently no effective long-term treatment for ovarian cancer (OC) resistant to poly-chemotherapy regimens based on platinum drugs. Preclinical and clinical studies have demonstrated a strong association between development of Pt-drug resistance ...

Abstract	There is currently no effective long-term treatment for ovarian cancer (OC) resistant to poly-chemotherapy regimens based on platinum drugs. Preclinical and clinical studies have demonstrated a strong association between development of Pt-drug resistance and increased thymidylate synthase (hTS) expression, and the consequent cross-resistance to the hTS inhibitors 5-fluorouracil (5-FU) and raltitrexed (RTX). In the present work, we propose a new tool to combat drug resistance. We propose to treat OC cell lines, both Pt-sensitive and -resistant, with dual combinations of one of the four chemotherapeutic agents that are widely used in the clinic, and the new peptide, hTS inhibitor, [D-Gln
MeSH term(s)	Antimetabolites, Antineoplastic/pharmacology ; Apoptosis ; Cell Proliferation ; Drug Resistance, Neoplasm/drug effects ; Drug Therapy, Combination ; Enzyme Inhibitors/pharmacology ; Female ; Fluorouracil/pharmacology ; Humans ; Liposomes/chemistry ; Ovarian Neoplasms/drug therapy ; Ovarian Neoplasms/metabolism ; Ovarian Neoplasms/pathology ; Peptide Fragments/pharmacology ; Polyethylene Glycols/chemistry ; Quinazolines/pharmacology ; Thiophenes/pharmacology ; Thymidylate Synthase/antagonists & inhibitors ; Tumor Cells, Cultured
Chemical Substances	Antimetabolites, Antineoplastic ; Enzyme Inhibitors ; Liposomes ; Peptide Fragments ; Quinazolines ; Thiophenes ; Polyethylene Glycols (3WJQ0SDW1A) ; Thymidylate Synthase (EC 2.1.1.45) ; raltitrexed (FCB9EGG971) ; Fluorouracil (U3P01618RT)
Language	English
Publishing date	2020-06-23
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	2019364-6
ISSN	1422-0067 ; 1422-0067 ; 1661-6596
ISSN (online)	1422-0067
ISSN	1422-0067 ; 1661-6596
DOI	10.3390/ijms21124452
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Folic Acid-Peptide Conjugates Combine Selective Cancer Cell Internalization with Thymidylate Synthase Dimer Interface Targeting.

Marverti, Gaetano / Marraccini, Chiara / Martello, Andrea / D'Arca, Domenico / Pacifico, Salvatore / Guerrini, Remo / Spyrakis, Francesca / Gozzi, Gaia / Lauriola, Angela / Santucci, Matteo / Cannazza, Giuseppe / Tagliazucchi, Lorenzo / Cazzato, Addolorata Stefania / Losi, Lorena / Ferrari, Stefania / Ponterini, Glauco / Costi, Maria P

Journal of medicinal chemistry

2021 Volume 64, Issue 6, Page(s) 3204–3221

Abstract: Drug-target interaction, cellular internalization, and target engagement should be addressed to design a lead with high chances of success in further optimization stages. Accordingly, we have designed conjugates of folic acid with anticancer peptides ... ...

Abstract	Drug-target interaction, cellular internalization, and target engagement should be addressed to design a lead with high chances of success in further optimization stages. Accordingly, we have designed conjugates of folic acid with anticancer peptides able to bind human thymidylate synthase (hTS) and enter cancer cells through folate receptor α (FRα) highly expressed by several cancer cells. Mechanistic analyses and molecular modeling simulations have shown that these conjugates bind the hTS monomer-monomer interface with affinities over 20 times larger than the enzyme active site. When tested on several cancer cell models, these conjugates exhibited FRα selectivity at nanomolar concentrations. A similar selectivity was observed when the conjugates were delivered in synergistic or additive combinations with anticancer agents. At variance with 5-fluorouracil and other anticancer drugs that target the hTS catalytic pocket, these conjugates do not induce overexpression of this protein and can thus help combating drug resistance associated with high hTS levels.
MeSH term(s)	Antineoplastic Agents/chemistry ; Antineoplastic Agents/pharmacokinetics ; Antineoplastic Agents/pharmacology ; Catalytic Domain/drug effects ; Cell Line, Tumor ; Cell Proliferation/drug effects ; Drug Delivery Systems ; Enzyme Inhibitors/chemistry ; Enzyme Inhibitors/pharmacokinetics ; Enzyme Inhibitors/pharmacology ; Female ; Folate Receptor 1/metabolism ; Folic Acid/analogs & derivatives ; Folic Acid/pharmacokinetics ; Folic Acid/pharmacology ; Humans ; Models, Molecular ; Ovarian Neoplasms/drug therapy ; Ovarian Neoplasms/metabolism ; Peptides/chemistry ; Peptides/pharmacokinetics ; Peptides/pharmacology ; Thymidylate Synthase/antagonists & inhibitors ; Thymidylate Synthase/metabolism
Chemical Substances	Antineoplastic Agents ; Enzyme Inhibitors ; Folate Receptor 1 ; Peptides ; Folic Acid (935E97BOY8) ; Thymidylate Synthase (EC 2.1.1.45)
Language	English
Publishing date	2021-03-12
Publishing country	United States
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	218133-2
ISSN	1520-4804 ; 0022-2623
ISSN (online)	1520-4804
ISSN	0022-2623
DOI	10.1021/acs.jmedchem.0c02107
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.B 151: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG)
Zs.MB 1: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Distinct DNA Methylation Profiles in Ovarian Tumors: Opportunities for Novel Biomarkers.

Losi, Lorena / Fonda, Sergio / Saponaro, Sara / Chelbi, Sonia T / Lancellotti, Cesare / Gozzi, Gaia / Alberti, Loredana / Fabbiani, Luca / Botticelli, Laura / Benhattar, Jean

International journal of molecular sciences

2018 Volume 19, Issue 6

Abstract: Aberrant methylation of multiple promoter CpG islands could be related to the biology of ovarian tumors and its determination could help to improve treatment strategies. DNA methylation profiling was performed using the Methylation Ligation-dependent ... ...

Abstract	Aberrant methylation of multiple promoter CpG islands could be related to the biology of ovarian tumors and its determination could help to improve treatment strategies. DNA methylation profiling was performed using the Methylation Ligation-dependent Macroarray (MLM), an array-based analysis. Promoter regions of 41 genes were analyzed in 102 ovarian tumors and 17 normal ovarian samples. An average of 29% of hypermethylated promoter genes was observed in normal ovarian tissues. This percentage increased slightly in serous, endometrioid, and mucinous carcinomas (32%, 34%, and 45%, respectively), but decreased in germ cell tumors (20%). Ovarian tumors had methylation profiles that were more heterogeneous than other epithelial cancers. Unsupervised hierarchical clustering identified four groups that are very close to the histological subtypes of ovarian tumors. Aberrant methylation of three genes (
MeSH term(s)	Biomarkers, Tumor/metabolism ; Cluster Analysis ; DNA Methylation/genetics ; Female ; Humans ; Kaplan-Meier Estimate ; Ovarian Neoplasms/genetics ; Promoter Regions, Genetic
Chemical Substances	Biomarkers, Tumor
Language	English
Publishing date	2018-05-24
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	2019364-6
ISSN	1422-0067 ; 1422-0067 ; 1661-6596
ISSN (online)	1422-0067
ISSN	1422-0067 ; 1661-6596
DOI	10.3390/ijms19061559
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: Proteomic and Bioinformatic Studies for the Characterization of Response to Pemetrexed in Platinum Drug Resistant Ovarian Cancer.

Severi, Leda / Losi, Lorena / Fonda, Sergio / Taddia, Laura / Gozzi, Gaia / Marverti, Gaetano / Magni, Fulvio / Chinello, Clizia / Stella, Martina / Sheouli, Jalid / Braicu, Elena I / Genovese, Filippo / Lauriola, Angela / Marraccini, Chiara / Gualandi, Alessandra / D'Arca, Domenico / Ferrari, Stefania / Costi, Maria P

Frontiers in pharmacology

2018 Volume 9, Page(s) 454

Abstract: Proteomics and bioinformatics are a useful combined technology for the characterization of protein expression level and modulation associated with the response to a drug and with its mechanism of action. The folate pathway represents an important target ... ...

Abstract	Proteomics and bioinformatics are a useful combined technology for the characterization of protein expression level and modulation associated with the response to a drug and with its mechanism of action. The folate pathway represents an important target in the anticancer drugs therapy. In the present study, a discovery proteomics approach was applied to tissue samples collected from ovarian cancer patients who relapsed after the first-line carboplatin-based chemotherapy and were treated with pemetrexed (PMX), a known folate pathway targeting drug. The aim of the work is to identify the proteomic profile that can be associated to the response to the PMX treatment in pre-treatement tissue. Statistical metrics of the experimental Mass Spectrometry (MS) data were combined with a knowledge-based approach that included bioinformatics and a literature review through ProteinQuest™ tool, to design a protein set of reference (PSR). The PSR provides feedback for the consistency of MS proteomic data because it includes known validated proteins. A panel of 24 proteins with levels that were significantly different in pre-treatment samples of patients who responded to the therapy vs. the non-responder ones, was identified. The differences of the identified proteins were explained for the patients with different outcomes and the known PMX targets were further validated. The protein panel herein identified is ready for further validation in retrospective clinical trials using a targeted proteomic approach. This study may have a general relevant impact on biomarker application for cancer patients therapy selection.
Language	English
Publishing date	2018-05-08
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	2587355-6
ISSN	1663-9812
ISSN	1663-9812
DOI	10.3389/fphar.2018.00454
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Intracellular quantitative detection of human thymidylate synthase engagement with an unconventional inhibitor using tetracysteine-diarsenical-probe technology.

Ponterini, Glauco / Martello, Andrea / Pavesi, Giorgia / Lauriola, Angela / Luciani, Rosaria / Santucci, Matteo / Pelà, Michela / Gozzi, Gaia / Pacifico, Salvatore / Guerrini, Remo / Marverti, Gaetano / Costi, Maria Paola / D'Arca, Domenico

Scientific reports

2016 Volume 6, Page(s) 27198

Abstract: Demonstrating a candidate drug's interaction with its target protein in live cells is of pivotal relevance to the successful outcome of the drug discovery process. Although thymidylate synthase (hTS) is an important anticancer target protein, the ... ...

Abstract	Demonstrating a candidate drug's interaction with its target protein in live cells is of pivotal relevance to the successful outcome of the drug discovery process. Although thymidylate synthase (hTS) is an important anticancer target protein, the efficacy of the few anti-hTS drugs currently used in clinical practice is limited by the development of resistance. Hence, there is an intense search for new, unconventional anti-hTS drugs; there are approximately 1600 ongoing clinical trials involving hTS-targeting drugs, both alone and in combination protocols. We recently discovered new, unconventional peptidic inhibitors of hTS that are active against cancer cells and do not result in the overexpression of hTS, which is a known molecular source of resistance. Here, we propose an adaptation of the recently proposed tetracysteine-arsenic-binding-motif technology to detect and quantitatively characterize the engagement of hTS with one such peptidic inhibitor in cell lysates. This new model can be developed into a test for high-throughput screening studies of intracellular target-protein/small-molecule binding.
Language	English
Publishing date	2016-06-02
Publishing country	England
Document type	Journal Article
ZDB-ID	2615211-3
ISSN	2045-2322 ; 2045-2322
ISSN (online)	2045-2322
ISSN	2045-2322
DOI	10.1038/srep27198
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Full text

Order via subito

Details ▾
- Full text online
- Order with fees

Article: Promoter methylation and downregulated expression of the

Gozzi, Gaia / Chelbi, Sonia T / Manni, Paola / Alberti, Loredana / Fonda, Sergio / Saponaro, Sara / Fabbiani, Luca / Rivasi, Francesco / Benhattar, Jean / Losi, Lorena

Oncology letters

2016 Volume 12, Issue 4, Page(s) 2811–2819

Abstract: ... ...

Abstract	TBX15
Language	English
Publishing date	2016-08-16
Publishing country	Greece
Document type	Journal Article
ZDB-ID	2573196-8
ISSN	1792-1082 ; 1792-1074
ISSN (online)	1792-1082
ISSN	1792-1074
DOI	10.3892/ol.2016.5019
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

To top

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito